WELL Health Enters into Automatic Share Purchase Plan
VANCOUVER, British Columbia--(BUSINESS WIRE)--WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (' WELL ' or the ' Company '), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, announced today that it has entered into an automatic share purchase plan (' ASPP ') with a broker in order to facilitate repurchases of the Company's common shares (' Common Shares ') under its previously announced normal course issuer bid (' NCIB ').
WELL previously announced that it had received approval from the Toronto Stock Exchange (' TSX ') to, during the 12-month period commencing May 20, 2025 and terminating May 19, 2026, purchase up to 6,326,417 Common Shares, representing approximately 2.5% of the 253,056,708 Common Shares issued and outstanding as of May 7, 2025, by way of a NCIB on the TSX or through Canadian alternative trading systems or by such other means as may be permitted under applicable law.
During the effective period of WELL's ASPP, WELL's broker may purchase Common Shares at times when WELL would not be active in the market due to insider trading rules and its own internal trading blackout periods. Purchases will be made by WELL's broker based upon parameters set by WELL when it is not in possession of any undisclosed material information about itself and its securities, and in accordance with the terms of the ASPP. Outside of the effective period of the ASPP, Common Shares may continue to be purchased in accordance with WELL's discretion, subject to applicable law. The ASPP has been entered into in accordance with the requirements of applicable Canadian securities laws.
WELL HEALTH TECHNOLOGIES CORP.
Per: 'Hamed Shahbazi'
Hamed Shahbazi
Chief Executive Officer, Chairman and Director
About WELL Health Technologies Corp.
WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 200 clinics supporting primary care, specialized care, and diagnostic services. In the United States WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: www.well.company.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
IDEX Biometrics ASA: Final result of the Subsequent Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice from IDEX Biometrics ASA (the "Company") on 21 May 2025 regarding the commencement of the subscription period (the "Subscription Period") in the subsequent offering (the "Subsequent Offering") consisting of up to 600,000,000 new shares (the "Offer Shares") in the Company at a subscription price of NOK 0.01 per share ("Offer Price"). The Subscription Period commenced on 22 May 2025 and expired on 5 June 2025. By the end of the Subscription Period, the Subsequent Offering was 8x oversubscribed. Pursuant to the resolution by the Extraordinary General Meeting dated 11 April 2025, the Company's board of directors has today resolved to allocate and issue a total of 600,000,000 Offer Shares at the Offer Price in accordance with the allocation criteria set out in the prospectus dated 21 May 2025, raising gross proceeds of NOK 6 million. Investors that are allocated Offer Shares can access information on the number of Offer Shares allocated to them through VPS on or about 6 June 2025. The due date for payment of the Offer Shares is on 11 June 2025. Subject to duly and timely payment of the Offer Shares, the share capital increase pertaining to the Subsequent Offering is expected to be registered in the Norwegian Register of Business Enterprises ('NRBE') on or about 13 June 2025. Following registration of the share capital increase associated with the Subsequent Offering in the NRBE, the Company's share capital will be NOK 44,316,309.99 consisting of 4,431,630,999 shares, each having a par value of NOK 0.01. The Offer Shares will be delivered to the VPS accounts of the subscribers shortly thereafter, expected on or about 13 June 2025. A separate announcement will be made when the share capital increase has been registered. The Offer Shares will have equal rights and rank pari passu with the Company's other shares. Arctic Securities AS is acting as manager in connection with the Subsequent Offering (the "Manager"). Ræder Bing advokatfirma AS is acting as the Company's legal advisor. For further information, please contact: Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@ IMPORTANT NOTICE This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering in the United States or to conduct a public offering of securities in the United States. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The "Prospectus Regulation" means Regulation (EU) 2017/1129, as amended (together with any applicable implementing measures) in any Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. The issue, subscription or purchase of shares in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assume any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believe that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond their control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not make any guarantee that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this announcement. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. This announcement is an advertisement and is not a prospectus for the purposes of the Prospectus Regulation as implemented in any Member State. About IDEX Biometrics: IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market. For more information, visit About this notice: This notice was issued by Kristian Flaten, CFO, on 6 June 2025 at 17:20 CET on behalf of IDEX Biometrics ASA. The information is published in accordance with section 5-8 of the Norwegian Securities Trading Act (STA) and released in accordance with section 5-12 of the in to access your portfolio
Yahoo
an hour ago
- Yahoo
The BC Centre for Excellence in HIV/AIDS national Summit raises alarm about rising incidence of HIV in Canada and threats to global progress
Delegates call on Prime Minister to end the Canadian epidemic and lead the worldwide HIV response in light of dramatic US cuts to treatment and care VANCOUVER, BC, June 6, 2025 /CNW/ - The BC Centre for Excellence in HIV/AIDS (BC-CfE) is hosting a national Summit of medical and HIV experts to raise the alarm about the rising incidence of HIV in Canada, the immense threat that US cuts to HIV programs pose to millions at risk of disease and death globally, and the need for Canadian leadership to help prevent a resurgence in HIV/AIDS. Despite the groundbreaking work done to implement the BC-CfE's Treatment as Prevention® (TasP®) and HIV Pre-Exposure Prophylaxis (PrEP) programs in many jurisdictions, Canada is losing ground to HIV/AIDS across the country. The latest available government statistics for 2023 show a 35% uptick in HIV cases in Canada compared to 2022. Anecdotal discussions between BC-CfE and HIV experts across Canada indicate the situation continues to deteriorate, with HIV incidence statistics expected to be higher yet again in 2024 and in 2025. Meanwhile, the United States has substantially decreased funding to domestic programs currently supported by the US Centers for Disease Control and Prevention and Medicare, and international programs supported by PEPFAR (the US President's Emergency Plan for AIDS Relief) and USAID. UNAIDS estimates another 6.6 million new HIV infections and 4.2 million AIDS-related deaths between 2025 and 2029 if US government cuts continue. At the National TasP Summit, Dr. Julio Montaner, BC-CfE Executive Director & Physician-in-Chief, called on Prime Minister Mark Carney to take the reins and redouble efforts to end the Canadian HIV/AIDS epidemic by 2030, fully fund Highly Active Antiretroviral Therapy (HAART) and PrEP within a national pharmacare plan, and meet the UNAIDS 95-95-95 target for HIV testing, treatment and viral suppression. Meeting the UNAIDS targets* would result in a 90% reduction in HIV/AIDS-related deaths and new infections by 2030, ending the HIV/AIDS epidemic as a public health threat. "The Prime Minister has called for cost-effective, nation-building projects to improve the lives of Canadians and show leadership," said Dr. Montaner. "Redoubling efforts to defeat HIV/AIDS in Canada by 2030 fits the bill. It saves lives, prevents disease progression, improves quality of life and saves money. We have a plan. We need the Prime Minister's help to get it over the finish line." In addition, Canada must step up to better support the Global Fund to Fight AIDS, Tuberculosis and Malaria, to provide much-needed international leadership in a renewed and reinvigorated fight against HIV/AIDS. Weakening global efforts for HIV prevention, treatment, and support are already having an impact in British Columbia and throughout Canada. Domestically, HIV prevention and treatment strategies have saved countless lives and dramatically improved the lives of people living with and at-risk of HIV. However, many of Canada's new HIV cases relate to domestic and international migration, demonstrating the need for federal unity in Canada's HIV response and better support for the Global Fund. "HIV does not respect provincial, Canadian or international borders," said Summit co-chair Dr. Val Montessori, BC-CfE Director of Clinical Education. "With new HIV diagnoses rising across Canada, the need is greater than ever to implement proven HIV prevention and treatment strategies. By working together, we can strengthen the national HIV response in Canada and around the world, improve the lives of people living with HIV, and prevent new cases." *About the UNAIDS 95-95-95 Targets Based on the Treatment as Prevention strategy developed by the BC-CfE, the United Nations Joint Programme on HIV/AIDS (UNAIDS) set out ambitious targets in 2014 to end the AIDS epidemic globally by 2030. This culminated in the UN 95-95-95 Targets, which established that countries ensure 95% of people living with HIV are diagnosed, 95% of those diagnosed are on treatment, and 95% of those on treatment are virally suppressed, by the year 2025. Meeting the UN Targets would change the trajectory of the epidemic so that we would see a 90% reduction in HIV/AIDS related deaths and new HIV infections by 2030, which would herald the end of the HIV/AIDS epidemic as a public health threat. About the British Columbia Centre for Excellence in HIV/AIDS The BC Centre for Excellence in HIV/AIDS (BC-CfE) is Canada's largest HIV/AIDS research, treatment and education facility – nationally and internationally recognized as an innovative world leader in combating HIV/AIDS and related diseases. The made-in-BC Treatment as Prevention® strategy (TasP®) pioneered by BC-CfE, and adopted by UNAIDS since 2011, inspired the ambitious global target for HIV treatment – known as the United Nations' 90-90-90 Target by 2020 and current UN 95-95-95 Target by 2025 – to end AIDS as a pandemic by 2030. The BC-CfE is applying TasP® to therapeutic areas beyond HIV/AIDS, including viral hepatitis and addiction, to promote Targeted Disease Elimination® as a means to contribute to healthcare sustainability. The BC-CfE works in close collaboration with key stakeholders, including government, health authorities, health care providers, academics, and the community to decrease the health burden of HIV/AIDS, hepatitis C and addictions across Canada and around the world. SOURCE British Columbia Centre for Excellence In HIV/AIDS View original content to download multimedia: Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the "Shareholders") held yesterday on June 5, 2025 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 17, 2025 (the "Circular") to its Shareholders were approved. Results of the matters voted on at the Meeting are set out below. Election of Directors Spectral's seven director nominees were elected: Nominee Votes For (percent) Votes Withheld (percent) Jan D'Alvise 99.78% 0.22% Jun Hayakawa 99.79% 0.21% Chris Seto 89.39% 10.61% William Stevens 99.50% 0.50% Paul Walker 97.67% 2.33% David W. Feigal, Jr. 99.67% 0.33% Cristiano Franzi 99.78% 0.22% Appointment of Auditors MNP LLP, Chartered Accountants, was re-appointed as auditor of Spectral. Votes For: 99.95% Votes Withheld: 0.05% About Spectral Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX'). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively over 360,000 times to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year. The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis The trial methods are detailed in 'Bayesian methods: a potential path forward for sepsis trials'. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the company's ability to raise capital and the availability of funds and resources to pursue R&D projects, the recruitment of additional clinical trial sites, the rate of patient enrollment, the successful and timely completion of clinical studies, the success of Baxter's commercialization efforts, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For further information, please contact: Ali MahdaviCapital Markets & Investor RelationsSpinnaker Capital Markets Inc.416-962-3300am@
